Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
Titel:
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
Auteur:
Egle, Alexander Steurer, Michael Melchardt, Thomas Weiss, Lukas Gassner, Franz Josef Zaborsky, Nadja Geisberger, Roland Catakovic, Kemal Hartmann, Tanja Nicole Pleyer, Lisa Voskova, Daniela Thaler, Josef Lang, Alois Girschikofsky, Michael Petzer, Andreas Greil, Richard